Home > Urology > EAU 2020 > Reduced BCG frequency = faster NMIBC recurrence

Reduced BCG frequency = faster NMIBC recurrence

Reduction in the frequency of Bacillus Calmette-Guérin (BCG) vaccine instillations during induction and maintenance treatment for non-muscle-invasive bladder cancer (NMIBC) results in earlier disease recurrence relative to a standard instillation schedule.

Prof. Marc-Oliver Grimm (University Hospital Jena, Germany) presented an analysis of the recurrence risk in patients with high grade NMIBC in the randomised phase 3 NIMBUS trial [1]. Prof. Grimm explained that, given the BCG shortage and the known BCG-associated toxicities, NIMBUS set out to investigate whether a reduced frequency of BCG instillations during induction and maintenance would result in noninferior clinical efficacy, with potentially fewer adverse events, as well as reduced inconvenience and cost. The primary endpoint was time to first recurrence. Key secondary outcomes were the number and grade of recurrent tumours, the rate of progression to muscle-invasive disease, and safety.

At d...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on